Why share your AMR Surveillance Data?

In 2016, a number of pharmaceutical companies signed the AMR Industry Declaration and the Industry Roadmap for Progress on Combating Antimicrobial Resistance in which they agreed to “continue to share the surveillance data we generate with public health bodies and healthcare professionals, and work with them to improve understanding of resistance trends, inform appropriate antibiotic and vaccine use and, over time, thereby help increase surveillance capabilities globally”.

In 2020 the members of the AMR Industry Alliance recommitted to surveillance data sharing echoing the Davos Declaration and the Industry Roadmap on Combatting AMR. There is an opportunity to bring in more pharma, generic and diagnostic companies.

In 2021 G7 Health Ministers’ Communique acknowledges the issue of AMR.

“..we must act strongly and across disciplines if we are to curb the silent pandemic of antimicrobial resistance. We recognise the importance of the research and development in new and innovative antimicrobials as well as alternatives to antimicrobials; vaccines, diagnostics and other countermeasures; and the need to take bolder steps to mitigate, minimise and contain the risk of AMR..”

Access To Medicine AMR Benchmark scorecard includes antimicrobial surveillance with maximum points awarded for companies that collect and share raw surveillance data on an open platform

UN Call to Action on Antimicrobial Resistance 2021:

“we commit to…strengthen effective and integrated AMR surveillance systems, addressing AMR in infection prevention and control, stewardship, monitoring, regulatory frameworks, enforcement; promote integrated target setting and share best practice, scientific knowledge and technical assistance between countries and regions, upon their request.”

The platform is linked to Make-data-count to enable the tracking of metrics associated with data re-use.